Open AccessFurther Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes
Author(s) -
Efrat Harel,
Jun Shoji,
Vivek C. Abraham,
Loan Miller,
Zoltán Lászik,
Andrew King,
Deján Dobi,
Gyula Szabó,
Byron Hann,
Minnie M. Sarwal,
Charles S. Craik,
Flavio Vincenti
Publication year - 2020
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000002930
Subject(s) - urokinase receptor , supar , podocyte , receptor , cancer research , urokinase , plasminogen activator , microbiology and biotechnology , medicine , biology , kidney , endocrinology , chemistry , proteinuria
The role of the soluble urokinase plasminogen activator receptor (suPAR) in focal segmental glomerulosclerosis (FSGS) as the circulating factor or as a predictor of recurrence after transplantation remains controversial. Previously published studies in mice and isolated podocytes produced conflicting results on the effect of suPAR on podocyte injury, effacement of foot processes, and proteinuria. These discordant results were in part due to diverse experimental designs and different strains of mice. The aim of our study was to determine the reasons for the inconsistencies of the previous studies results with suPAR by using uniform methods and studies in different strains of mice.